The anti-PD-1 or anti-PD-L1 antibodies can reactivate CTLs in cancers by disrupting the PD-1/PD-L1 axis, and enhancing anti-tumor activity across various solid tumors, such as gastric, colorectal, and lung cancers (6–9). Here, PDCD1 is linked to neoplasm.